Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis

医学 内科学 肿瘤科 梅德林 癌症 临床试验 免疫疗法 疾病 放射治疗 癌 化疗
作者
Yaping Zhang,Shangbin Kao,Dian Li,Canlong Yan,Biao Huang,Hongming Fang
出处
期刊:Future Oncology [Future Medicine]
卷期号:22 (12): 1439-1451
标识
DOI:10.1080/14796694.2026.2659354
摘要

PURPOSE: The optimal treatment strategy for advanced or metastatic gastric, gastro-esophageal junction or esophageal carcinomas expressing Claudin-18 isoform 2 (CLDN18.2) remains inadequately defined and requires further investigation. METHODS: A systematic search was conducted to identify randomized controlled trials and single-arm studies. RESULTS: Four randomized controlled trials comprising five cohorts compared anti-CLDN18.2-based therapies with chemotherapy or physician's choice. Anti-CLDN18.2 therapy, primarily consisting of first-line zolbetuximab combined with chemotherapy, significantly improved progression-free survival (PFS) (hazard ratios [HR] 0.564; 95% confidence interval [CI]: 0.417-0.711) and overall survival (OS) (HR 0.716; 95% CI: 0.631-0.802), along with enhanced 1- and 2-year survival rates. However, higher rates of nausea, neutropenia, and vomiting were observed in patients treated with zolbetuximab-based regimens. A single-arm meta-analysis, which included ten cohorts from seven trials, demonstrated that antibody-drug conjugates (ADCs) exhibited greater antitumor activity compared to zolbetuximab-based regimens. CONCLUSION: Anti-CLDN18.2 therapies, particularly first-line zolbetuximab plus chemotherapy, significantly improve PFS and OS in advanced gastric, gastro-esophageal junction, or esophageal carcinoma compared to standard treatments. ADCs have shown promising antitumor activity in single-arm studies, suggesting the need for confirmatory randomized trials. Standardized definitions for CLDN18.2 positivity and high expression are urgently needed. PROTOCOL REGISTRATION: www.crd.york.ac.uk/prospero identifier is CRD420251123719.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
怕黑的白玉完成签到,获得积分10
刚刚
1秒前
zzyh完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
1秒前
2秒前
2秒前
2秒前
2秒前
轩辕十四完成签到,获得积分10
3秒前
斯文败类的应助被Akiba采纳,获得10
3秒前
岳志伟关注了科研通微信公众号
4秒前
斯文败类的应助被Joehq_1203采纳,获得10
4秒前
5秒前
5秒前
5秒前
5秒前
Nole的应助被今天没有哭鸭采纳,获得10
5秒前
Maestro_S的应助被shaco采纳,获得10
5秒前
lili完成签到,获得积分10
5秒前
脑洞疼的应助被15331970326采纳,获得10
6秒前
无极微光的应助被zhoudongxue采纳,获得20
6秒前
7秒前
朱晖发布了新的文献求助20
7秒前
今夜略闲发布了新的文献求助10
7秒前
7秒前
喔喔佳佳L发布了新的文献求助20
7秒前
入司的应助被李麟采纳,获得10
7秒前
Akim的应助被刘泽楷采纳,获得10
8秒前
英姑的应助被楠楠采纳,获得10
8秒前
8秒前
orixero的应助被annona采纳,获得30
8秒前
8秒前
9秒前
瘦瘦大米发布了新的文献求助10
9秒前
月亮完成签到,获得积分10
9秒前
Lucas的应助被Kyra采纳,获得10
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139